相关实验视频

Updated: Mar 9, 2026

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

叶酸改善了糖尿病足部的愈合

Glenn D Hoke¹, Annjanette Stone², Michael A Bauer³

¹Departments of Surgery/Plastic Surgery, Richmond Department of Veterans Affairs, Medical Center, Richmond, Virginia, USA.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society

|March 8, 2026

概括

一种新的叶酸 (FA) 伤口治疗方法显著改善了慢性糖尿病足 (DFU) 的愈合. 这种治疗减少了炎症标志物,促进了细胞修复,促进了DFU重新表皮化.

科学领域:

生物化学生物化学
皮肤病学皮肤病学
分子生物学分子生物学

背景情况:

慢性糖尿病足 (DFU) 代表了严重的临床挑战,治疗能力受损.
炎症和失调的细胞信号通路有助于DFU的慢性.

研究的目的:

评估一种新型叶酸 (FA) 伤口治疗 (FAWT) 在促进慢性DFU的愈合方面的疗效.
研究FAWT对角质细胞和炎症通路的影响背后的分子机制.

主要方法:

这是一项双盲随机对照试验 (RCT),涉及10名慢性DFU受试者,将FAWT (PluroGel含2.5%FA) 与对照 (PluroGel) 进行比较.
使用反相蛋白质组 (RPPA) 的蛋白质组分析,以评估角质细胞中的蛋白质水平 (HMGB1,IL-1B) 和酸化 (SAP/JNK3,p38 MAPK).
基因组DNA甲基化分析,以评估微RNA (MiRNA) 调节的变化.

主要成果:

在12周后,FAWT显著改善了DFU的愈合,DFU面积减少了88%,而对照组的40%相比.
FAWT显著降低了促炎蛋白HMGB1和IL-1B的水平,并降低了SAP/JNK3和p38 MAPK通路的激活.
FAWT诱导了抗炎MiRNAs调节部位的DNA甲基化减少,这表明MAPK信号的表达增加和潜在抑制.

结论:

通过调节炎症反应和细胞信号传递,FAWT有效地促进DFU重新表皮化.
治疗似乎诱导了抗炎MiRNA表达,导致促炎媒介体 (HMGB1,IL-1B) 的减少和MAPK通路激活的减少.
FAWT促进DFU从炎症状态过渡到修复阶段,支持角质细胞的增殖,迁移和重新表皮化.

关键词:

通过DNA甲基化.这就是HMGB1的特点.糖尿病足糖尿病足糖尿病的伤口叶酸是叶酸中的一种.基因组基因组学这是一种炎症炎症炎症炎症.这是一个微型RNA.蛋白质基质的保护性

更多相关视频

A Simplified Technique for Producing an Ischemic Wound Model

A Simplified Technique for Producing an Ischemic Wound Model

Published on: May 2, 2012

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing

Published on: December 13, 2024

相关概念视频

Peripheral Artery Disease IV: Nursing Management

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...